Story perspectives

Trans Advocates Slam Controversial Puberty Blocker Study

1/21/2026

Summary

Story summary

Transgender rights advocates in the U.K. criticize two new puberty blockers studies as unethical and biased.
The Pathways Trial, announced by NHS researchers, will compare immediate versus delayed treatment on 226 participants aged 10–16.
Critics, including TransActual (a nonprofit advocacy group), allege the study violates ethics and coerces participation, citing informed-consent concerns.
Backlash labels the trial as activist ideology masquerading as research, while supporters claim it could provide necessary evidence.

1 of 1

Story summary

Transgender rights advocates in the U.K. criticize two new puberty blockers studies as unethical and biased.
The Pathways Trial, announced by NHS researchers, will compare immediate versus delayed treatment on 226 participants aged 10–16.
Critics, including TransActual (a nonprofit advocacy group), allege the study violates ethics and coerces participation, citing informed-consent concerns.
Backlash labels the trial as activist ideology masquerading as research, while supporters claim it could provide necessary evidence.